Source: Healio News
The FDA granted orphan drug designation to ALLO-715 for the treatment of advanced multiple myeloma, according to the agent’s manufacturer.
ALLO-715 (Allogene Therapeutics) is an allogeneic, gene-edited chimeric antigen receptor T-cell therapy that targets the B-cell maturation antigen (BCMA) on the surface of cancer cells.
The agent — which comprises induced pluripotent stem cells from healthy donors — disrupts the T-cell receptor-alpha constant gene to reduce risk for graft-versus-host disease after infusion.
ALLO-715 also uses proprietary transcription activator-like effector